The FDA approval makes Adstiladrin the first gene therapy to be approved for adult patients with high-risk BCG-unresponsive NMIBC with CIS.

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non ...

As announced in January 2024, ADSTILADRIN is fully available and accessible in the U.S. ADSTILADRIN has confirmed 99 percent coverage for commercial and government-insured patients.

The U.S. Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN ...

Continued strong performance in Reproductive Medicine which exceeded sales of €1 billion for the first time Adstiladrin ® (nadofaragene firadenovec-vncg), our novel gene-based therapy for ...

Adstiladrin® (nadofaragene firadenovec-vncg), our novel gene-based therapy for bladder cancer, emerged as a second growth driver following the first full year of U.S. sales ...

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin For more information, please contact Carine Julen Senior Manager, Corporate Communications ...